BERKELEY HEIGHTS, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- via IBN — Lucy Scientific Discovery Inc. (NASDAQ: LSDI) today announces its placement in...
Niagara Falls, NY, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular...
WALTHAM, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Marijuana DeScheduling News Much To Do Over NothingWASHINGTON D.C. / ACCESSWIRE / September 8, 2023 / Attorney Megan Sheehan representing...
TORONTO, ON / ACCESSWIRE / September 7, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), is a clinical...
Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public...
San Diego, California--(Newsfile Corp. - September 7, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary...
HumanFirst's new solution aligns AI-powered biomarkers and clinical outcome assessments (COAs) across one platform to drive scientific progress, R&D efficiencies,...
DANBURY, Conn. and SANTA ANA, Calif., Sept. 7, 2023 /PRNewswire/ -- Framework Solutions ("Frameworks"), a provider of clinical to commercial...
FARMINGTON HILLS, Mich., Sept. 7, 2023 /PRNewswire/ -- LSPedia, a software-as-a-service (SaaS) provider specializing in product traceability solutions for the...
- 2023 recipients include patient advocacy organizations in Australia and Brazil - SOUTH PLAINFIELD, N.J., Sept. 7, 2023 /PRNewswire/ --...
BEIJING, Sept. 7, 2023 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to...
Completion of enrollment of study on track by end of 2023Topline data results from interim analysis also on track to...
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion...
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport...
Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase...
Table 1 Table 1 Chart 1 Chart 1 Chart 2 Chart 2 Table 2 Table 2All study objectives were met,...
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...